Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Sofie Kirial MørkSigne Koggersbøl SkadborgBenedetta AlbieriArianna DraghiKalijn Fredrike BolMohammad KadivarMarie Christine Wulff WestergaardJoachim Stoltenborg GranhøjAnnie BorchNadia Viborg PetersenNikolas ThuesenIda Svahn RasmussenLars Vibe AndreasenRebecca Bach DohnChristina Westmose YdeNis NoergaardTorben LorentzenAnders Bundgaard SoerensenDaniela Kleine-KohlbrecherAnders JespersenDennis ChristensenJens KringelumMarco DoniaSine Reker HadrupInge Marie SvanePublished in: Journal for immunotherapy of cancer (2024)
Immunization with EVX-01-CAF09b in addition to anti-PD-1 therapy was shown to be safe and well tolerated and elicit vaccine neoantigen-specific CD4+and CD8+ T cell responses at all dose levels. In addition, objective tumor responses were observed in 67% of patients. The results encourage further assessment of the antitumor efficacy of EVX-01 in combination with anti-PD-1 therapy.